Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.

Rob Wright highlights the “integrative thinking” work of Jennifer Riel and Roger Martin, professors at the Rotman School of Management, University of Toronto, in helping leaders make great choices, drawing on LEGO’s entry into feature films as an example.

Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.

Xencor’s story seems riddled with more than your average share of challenges, hurdles, and outright roadblocks. But it’s the outcome of that story — a growing company now valued at roughly $1.8 billion with nine drugs in the clinic and 150 employees — that truly make’s Xencor’s journey so compelling.

There are three things you should never talk about in polite company: religion, politics, and money. Still, I’d like to briefly discuss two of those — bear with me. 

Chris Anselmo provides his thoughts as a first time panelist and attendee of the 2019 BIO International Convention and Conference, Philadelphia, PA, June 3 - 6.

While the annual BIO International Convention and Conference has much in common with the annual J.P. Morgan Healthcare Conference, first time attendee of BIO, Matt Pillar, quickly picks up on key points of differentiation at BIO 2019 this year in Philadelphia, PA, June 3 - 6.

Whether it’s product promotion or pricing practices, biopharma’s inability to envision long-term consequences when implementing short-term decisions further handicaps what it is trying to do.

So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.